In Brief: Medstone International
This article was originally published in The Gray Sheet
Executive Summary
Medstone International: Submits premarket approval application to FDA for use of its STS lithotripter device for treatment of gallstones in conjunction with Novartis' Actigall (ursodiol) gallstone dissolution medication, Medstone announces Sept. 4. The STS lithotripter, a shockwave generating device, is already approved for treatment of kidney stones. The combination therapy for gallstones is anticipated to speed clearance of the stones compared to drug therapy alone, the firm states. Medstone had suspended efforts to pursue FDA approval for biliary lithotripsy in 1990 due to the cost of FDA's requirement that PMAs include data comparing lithotripsy/ursodiol treatment to ursodiol alone; a Medstone PMA supplement for the indication was rejected by the agency in 1989 due to a lack of an Actigall-alone cohort. The new submission includes "an analysis of clinical trials for Actigall monotherapy," made possible under a cooperative agreement with Novartis predecessor Ciba-Geigy ("The Gray Sheet" Jan. 8, 1996, I&W-9)...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.